塞多明基注射液治疗Rutherford 5级严重下肢缺血Ⅲ期临床试验（HOPE CLTI-2）论文

Seltoplasmid promotes ulcer healing versus placebo for treating patients with chronic limb-threatening ischemia: HOPE CLTI-2 trial

 Molecular Therapy. 2025 Apr 11:S1525-0016(25)00283-7. 

重组人肝细胞生长因子裸质粒治疗慢性缺血性疾病作用机制及注射位点选择的研究

Optimal injection sites for therapeutic angiogenesis: HGF-mediated regulation of HIF-1α via MAPK/PI3K pathways in hypoxic endothelial cells

Tissue and Cell (2025), doi: https://doi.org/10.1016/j.tice.2025.102871.

重组人肝细胞生长因子裸质粒治疗慢性缺血性疾病的系统评价与Meta分析

Recombinant Human Hepatocyte Growth Factor Plasmids for Treating Patients with Chronic Limb Threatening Ischaemia: A Systematic Review and Meta-analysis

European Journalof Vascular&EndovascularSurgery (2024)

https://doi.org/10.1016/j.ejvs.2024.07.016.

NL003II期临床试验长期随访结果论文

Nine-year follow-up of patients receiving recombinant human hepatocyte growth factor nude plasmid DNA for critical limb ischemia: Updated safety and efficacy results

Vascular Investigation and Therapy（ISSN:2589-9686) DOI:10.4103/vit_21_24

NL003 III期临床试验方案论文

Rationale and design for the study of recombinant human hepatocyte growth factor plasmid in the treatment of patients with chronic limb-threatening ischemia (HOPE CLTI): Randomized, placebo-controlled, double-blind, phase III clinical trials

American heart journal, vol. 2022 Aug 21;254:88-101.

NL003 II期临床试验论文

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia

Molecular Therapy. 2019 Dec 4;27(12):2158-2165.

NL003 I期临床试验论文

A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor to treat patients with critical limb ischemia.

The Journal of Gene Medicine. 2011 Nov;13(11):602-10.

NL005 I期临床试验论文

A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers

 Journal of Cellular and Molecular Medicine. 2021 Aug 4.doi: 10.1111/jcmm.16693.